Abbott and Exact Sciences Present Breakthrough Multi-Cancer Early Detection Data at AACR 2026
核心洞察
Abbott (搜索)'s Cancerguard (搜索) test demonstrates that combining methylation and protein biomarkers enables broader cancer detection, with nearly half of positive signals driven by methylation alone and additional detection from protein-only signals.
The DETECT-A study shows promising long-term outcomes with all patients treated for stage I or II cancers remaining alive and cancer-free after approximately four years of follow-up.
Exact Sciences (搜索) presents optimized multi-biomarker classifier data showing improved early-stage sensitivity while maintaining high specificity for their Cancerguard (搜索) test.
Abbott (搜索) and Exact Sciences (搜索) unveiled significant advances in multi-cancer early detection (MCED) technology at the American Association for Cancer Research (AACR) Annual Meeting 2026, presenting data that demonstrates how multi-biomarker approaches can improve early-stage cancer detection across multiple cancer types.
Multi-Biomarker Strategy Shows Superior Detection Performance
New data from Abbott (搜索)'s Cancerguard (搜索) test reveal how combining methylation and protein biomarkers enables broader cancer detection capabilities. In a prospectively collected case-control study, nearly half of positive cancer signals were driven by methylation alone (47.1%), with additional detection from protein-only signals (7.4%) and combined biomarker signals (45.5%).
"We designed Cancerguard (搜索) as the first-of-its-kind multi-biomarker test because no one signal tells the whole story," said Tom Beer, M.D., chief medical officer for multi-cancer early detection at Abbott (搜索)'s cancer diagnostics business. "By combining biomarkers, we can detect cancer earlier, when it matters most."
The research demonstrates that in early-stage disease, many cancer signals were detected by a single biomarker class, highlighting how each contributes uniquely to overall detection. Notably, none of the 2.6% false-positive results were positive for both biomarkers, supporting the test's specificity.
Long-Term Clinical Outcomes Support MCED Impact
The AACR Cancer Prevention Research Award for Outstanding Journal Article recognized a landmark publication reporting multi-year outcomes from the DETECT-A study, the first large prospective interventional trial of a blood-based MCED test. After a median follow-up of approximately four years, all patients treated for stage I or II cancers remained alive and cancer-free.
The DETECT-A study enrolled more than 10,000 women with no history of cancer to determine if a blood test combined with standard-of-care screenings could detect cancers before signs and symptoms appeared. The study identified nine cancer types, including several without routine screening.
"Long-term follow-up provides critical insight into how multi-cancer early detection can shape the future of cancer screening," Beer noted. "With nearly 70 percent of cancers occurring in types without recommended screening, these findings highlight the potential for MCED to increase early detection and improve outcomes."
Exact Sciences Advances Multi-Biomarker Innovation
Exact Sciences (搜索) presented complementary research demonstrating that methylation and protein biomarker classes provide independent contributions to cancer signal detection, particularly in early-stage disease. The company's optimized methylation-protein multi-cancer early detection classifier showed improved early-stage sensitivity compared with the prior version while maintaining high specificity.
"Our goal is to use molecular information to guide cancer care at every stage," said Jorge Garces, Ph.D., chief scientific officer at Exact Sciences (搜索). "By combining tumor-informed ctDNA analysis with multi-biomarker detection approaches, we're building tools that give clinicians a clearer view of cancer biology and how disease evolves over time."
Expanding Clinical Applications Beyond Early Detection
Exact Sciences (搜索) also presented data on molecular residual disease (MRD) testing, including findings from the NSABP B-59/GBG-96-GeparDouze trial evaluating its tumor-informed circulating tumor DNA test, Oncodetect (搜索), in early triple-negative breast cancer. Pre-surgery ctDNA status following neoadjuvant therapy was strongly associated with both pathologic complete response and distant recurrence-free interval.
Additional research showed that comprehensive tumor profiling identified actionable genomic alterations in nearly all breast and colorectal cancer patients tested for ctDNA, with approximately half of the samples having at least one alteration associated with FDA-approved therapies.
Technology Specifications and Availability
Cancerguard (搜索) is currently the only commercially available MCED test designed with a multi-biomarker class approach, combining methylation and protein signals. The test is designed to detect multiple cancers, including the most aggressive cancers, in early stages from a simple blood draw and follows a streamlined, imaging-based diagnostic pathway to help reduce unnecessary follow-up procedures.
The test has been developed with high specificity to minimize false positives and helps detect a wide range of cancers, including those that lack guideline-recommended screening options. However, the Cancerguard (搜索) test has not been cleared or approved by the U.S. Food and Drug Administration or any other regulatory authority.